A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel Treatment.
Phase of Trial: Phase IV
Latest Information Update: 04 Aug 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACRO QLQ
- Sponsors Ipsen
- 27 Jul 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 27 May 2016 Status changed from recruiting to active, no longer recruiting.